Related Experiment Video

Updated: Apr 20, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.8K

Respiratory Tract Infections Due to Human Metapneumovirus in Immunocompromised Children

Helen Y Chu1, Christian Renaud2, Elle Ficken2

  • 1Department of Medicine, University of Washington.

Journal of the Pediatric Infectious Diseases Society
|November 25, 2014
PubMed

Insights

Human metapneumovirus (hMPV) infections in immunocompromised children often lead to severe respiratory illness and death. Further research is needed to determine the effectiveness of treatments like ribavirin and immunoglobulin therapy.

Area of Science:

  • Pediatric Infectious Diseases
  • Immunocompromised Host Pathologies
  • Viral Respiratory Infections

Background:

  • Clinical presentation and management of human metapneumovirus (hMPV) in immunocompromised children remain poorly understood.
  • hMPV is a significant pathogen in vulnerable pediatric populations, necessitating a clearer understanding of its clinical impact.

Purpose of the Study:

  • To evaluate the clinical characteristics, management, and outcomes of hMPV infections in immunocompromised pediatric patients.
  • To identify risk factors associated with severe disease and mortality in this cohort.

Main Methods:

  • Retrospective analysis of pediatric patients with laboratory-confirmed hMPV infections.
  • Inclusion criteria encompassed patients with hematologic malignancy, solid tumors, solid organ transplant, rheumatologic disease, or chronic immunosuppression.
  • Statistical analysis included t tests and Fisher's exact tests.

Main Results:

  • Fifty-five immunocompromised children with hMPV infection were identified (median age 5 years).
  • Lower respiratory tract infections (LRTI) occurred in 29% of patients, with 23% requiring intensive care or high-flow oxygen.
  • Neutropenia was associated with severe disease; 5% of patients died from hMPV pneumonia.

Conclusions:

  • Immunocompromised pediatric patients with hMPV infection exhibit high rates of LRTI and mortality.
  • The efficacy of treatments such as ribavirin and intravenous immunoglobulin requires further investigation in this population.
  • Early identification and management strategies are crucial for improving outcomes in hMPV-infected immunocompromised children.
Abstract

Keywords:
human metapneumovirusimmunocompromisedpediatrictransplanttreatment

More Related Videos

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.5K
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.7K

Related Concept Videos

Microbiota of the Respiratory Tract01:29

Microbiota of the Respiratory Tract

The human respiratory tract, comprising the upper and lower segments, serves as a critical interface with the external environment. The upper respiratory tract (URT)—including the nostrils, sinuses, pharynx, and oropharynx—is heavily colonized by microbes, while the lower respiratory tract (LRT), composed of the larynx, trachea, bronchi, and lungs, was long thought to be sterile. However, recent molecular studies have revealed that the lungs are not devoid of microbes but act more...
47
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
16
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.4K
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
72
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
4.1K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
4.6K